2022 Orphan diseases outlook

25 January 2022

By Dr Nicola Davies

The year 2022 promises to continue the upward trajectory of development for orphan drugs. Financial projections from the previous year are expected to remain on course this year, with growth in the orphan drug market anticipated to increase from $190.8 billion in 2021 to $248.2 billion in 2026.1

Clinical trials for many drugs in development are expected to commence or continue into the new year. This year also brings with it a renewed focus on reducing costs associated with orphan drug products. In addition, governments and organizations around the world continue to explore opportunities to promote rare disease research and development (R&D), through grants and conferences scheduled to take place this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK